Skip to Content
Merck
  • Relationship between cerebral sigma-1 receptor occupancy and attenuation of cocaine's motor stimulatory effects in mice by PD144418.

Relationship between cerebral sigma-1 receptor occupancy and attenuation of cocaine's motor stimulatory effects in mice by PD144418.

The Journal of pharmacology and experimental therapeutics (2014-08-08)
John R Lever, Dennis K Miller, Emily A Fergason-Cantrell, Caroline L Green, Lisa D Watkinson, Terry L Carmack, Susan Z Lever
ABSTRACT

Psychostimulant effects of cocaine are mediated partly by agonist actions at sigma-1 (σ1) receptors. Selective σ1 receptor antagonists attenuate these effects and provide a potential avenue for pharmacotherapy. However, the selective and high affinity σ1 antagonist PD144418 (1,2,3,6-tetrahydro-5-[3-(4-methylphenyl)-5-isoxazolyl]-1-propylpyridine) has been reported not to inhibit cocaine-induced hyperactivity. To address this apparent paradox, we evaluated aspects of PD144418 binding in vitro, investigated σ1 receptor and dopamine transporter (DAT) occupancy in vivo, and re-examined effects on locomotor activity. PD144418 displayed high affinity for σ1 sites (Ki 0.46 nM) and 3596-fold selectivity over σ2 sites (Ki 1654 nM) in guinea pig brain membranes. No appreciable affinity was noted for serotonin and norepinephrine transporters (Ki >100 μM), and the DAT interaction was weak (Ki 9.0 μM). In vivo, PD144418 bound to central and peripheral σ1 sites in mouse, with an ED50 of 0.22 μmol/kg in whole brain. No DAT occupancy by PD144418 (10.0 μmol/kg) or possible metabolites were observed. At doses that did not affect basal locomotor activity, PD144418 (1, 3.16, and 10 μmol/kg) attenuated cocaine-induced hyperactivity in a dose-dependent manner in mice. There was good correlation (r(2) = 0.88) of hyperactivity reduction with increasing cerebral σ1 receptor occupancy. The behavioral ED50 of 0.79 μmol/kg corresponded to 80% occupancy. Significant σ1 receptor occupancy and the ability to mitigate cocaine's motor stimulatory effects were observed for 16 hours after a single 10.0 μmol/kg dose of PD144418.

MATERIALS
Product Number
Brand
Product Description

Haloperidol, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Haloperidol, powder
Sigma-Aldrich
1,3-Di-o-tolylguanidine, 99%
Supelco
Cocaine solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Desipramine hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
Haloperidol for system suitability, European Pharmacopoeia (EP) Reference Standard
Haloperidol for peak identification, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Piperazine, BioUltra, anhydrous, ≥99.0% (T)
Sigma-Aldrich
Fluoxetine hydrochloride, solid
Sigma-Aldrich
Desipramine hydrochloride, ≥98% (TLC), powder
Supelco
Fluoxetine hydrochloride, VETRANAL®, analytical standard
Desipramine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Supelco
Fluoxetine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material